SG Americas Securities
NPCE icon

SG Americas Securities’s Neuropace NPCE Stock Holding History

SG Americas Securities’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,640
Closed -$153K – 3582
2026
Q1 		$153K Buy
11,640
+4,029
+53% +$60.4K ﹤0.01% 2765
2025
Q4 		$118K Buy
+7,611
New +$102K ﹤0.01% 3159
2023
Q2 		– Sell
-25,388
Closed -$118K – 2883
2023
Q1 		$118K Buy
+25,388
New +$97.2K ﹤0.01% 2810

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SG Americas Securities's NPCE Position: Q2 2026 in Review

SG Americas Securities sold out of Neuropace (NPCE) in Q2 2026, closing a stake of 11,640 shares — an estimated $153K sold.

SG Americas Securities first reported a position in NPCE in Q1 2023 and held it in 3 quarters. The position peaked at $153K in Q1 2026. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • SG Americas Securities reported no remaining Neuropace position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 11,640 Neuropace shares in Q2 2026, an estimated $153K.
  • SG Americas Securities first reported a position in Neuropace in Q1 2023 and held it in 3 quarters.
  • SG Americas Securities's Neuropace position peaked at $153K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.